Engineered KRAS G12D-Reactive T Cells Show Promise in Pancreatic Cancer
- PMID: 35686834
- DOI: 10.1158/2159-8290.CD-RW2022-103
Engineered KRAS G12D-Reactive T Cells Show Promise in Pancreatic Cancer
Abstract
T cells with engineered KRAS G12D-specific TCRs mediated regression of metastases in a patient with pancreatic cancer.
©2022 American Association for Cancer Research.
Comment on
-
Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer.N Engl J Med. 2022 Jun 2;386(22):2112-2119. doi: 10.1056/NEJMoa2119662. N Engl J Med. 2022. PMID: 35648703 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
